Nonclinical Safety assessment of therapies targeting neoantigens

The "Nonclinical Safety assessment of therapies targeting neoantigens" is 1 of 10 courses included in the Cancer Immunotherapies module. 

This course is led by Dr. Gautham Rao at Genentech

 

Learning Objectives

The participant  will understand:

  1. Rationale for targeting neoantigens in the context of immunotherapy
  2. Mechanisms of action of neoantigen cancer vaccines and TCR-engineered T cells
  3. Evolving regulatory landscape and key guidance documents
  4. Considerations for preclinical safety assessment of neoantigen-targeting therapies
  5. Types of studies/assays to consider and how they support preclinical safety assessment
Course summary
Available credit: 
  • 1.00 Participation
Course opens: 
09/28/2022
Course expires: 
09/30/2027
Cost:
$25.00
Part of: 
Cancer Immunotherapies
Rating: 
0

Available Credit

  • 1.00 Participation

Price

Cost:
$25.00
Please login or register to take this course.